Photodynamic Therapy (PDT) Cholangiocarcinoma Registry (PDTRegistry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01524146|
Recruitment Status : Recruiting
First Posted : February 1, 2012
Last Update Posted : February 20, 2017
Currently, very few centers offer Photodynamic therapy for unresectable Cholangiocarcinoma in the United States. Several European studies have reported the efficacy and safety of Photodynamic Therapy (PDT) for Cholangiocarcinoma, however, only a few studies have reported the same in the United States.
The establishment of a registry to capture all PDT cases within and outside US can help the investigators evaluate a larger and non-ambiguous sample population. This would help the investigators evaluate the technical success rates, clinical success rates, feasibility and safety of PDT for unresectable cholangiocarcinoma. With more endoscopists considering PDT as a therapeutic option along with adjuvant treatment for cholangiocarcinoma, there is a need to further evaluate the efficacy and safety of such combined procedures as well. The ultimate objective is to assess if PDT with or without additional or adjuvant treatment options prolongs survival duration and improves quality of life in patients with unresectable cholangiocarcinoma.
This multicenter registry has been initiated:
- To document the impact of PDT on the clinical management of unresectable cholangiocarcinoma.
- To assess the clinical and technical success rates of PDT for unresectable cholangiocarcinoma.
|Condition or disease||Intervention/treatment|
|Unresectable Cholangiocarcinoma Biliary Obstruction Stent Obstruction Biliary Stricture||Procedure: Photodynamic Therapy|
PDT offers a number of practical advantages; it is minimally invasive and has a low complication rate, the procedure can easily be performed by a trained endoscopist, and it is well tolerated. In the trial conducted in Germany, the adverse events of PDT were mild to moderate, predictable, and relatively easy to control. Photosensitivity was the only systemic side effect (seen in only three patients). However, provided that simple guidelines for light exposure are followed, there is minimal risk to the patient, as shown by the low incidence of photosensitivity reactions in this study which all resolved.
A study from the Mayo group included 25 patients with unresectable cholangiocarcinoma who were treated with PDT from 1991 to 2004 showed that the time interval between diagnosis and treatment with PDT is an important predictor of survival following PDT even when adjusted for other potential factors that affect survival such as age, gender, Bismuth stage, presence of tumor mass on imaging and presence of extra biliary spread. Early treatment with PDT may lead to greater preservation of liver function. A recent study by the primary investigator has also recently reported improved survival in patients receiving PDT and stent compared to stent only (16.2 months vs 7.4 months).
Several other European studies have reported the efficacy and safety of PDT for cholangiocarcinoma; however, only a few studies have reported the same in the United States. This is again due to the fact that PDT is not offered as a therapeutic option for unresectable cholangiocarcinoma within US.
However, the establishment of a registry to capture all PDT cases within and outside US can help the investigators evaluate a larger and non ambiguous sample population. This would help the investigators evaluate the technical success rates, clinical success rates, feasibility and safety of PDT for unresectable cholangiocarcinoma.
The involvement of international sites is crucial, as the advanced endoscopists all over the world are offering photodynamic therapy for managing unresectable cholangiocarcinoma. However, because of the non-existence of a registry, and the fact that PDT is not offered in more than a few centers in the US; these cases are often reported with a smaller sample size. The registry hopes to combine all such comparable cases and collect enough relevant data for statistical analyses.
With more endoscopists considering PDT as a therapeutic option along with adjuvant treatment for cholangiocarcinoma, there is a need to further evaluate the efficacy and safety of such combined procedures as well. The ultimate objective is to assess if PDT with or without additional or adjuvant treatment options prolongs survival duration and improves quality of life in patients with unresectable cholangiocarcinoma.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||To Establish a Multicenter Registry to Evaluate the Impact of Photodynamic Therapy in the Management of Patients With Unresectable Cholangiocarcinoma.|
|Study Start Date :||November 2011|
|Estimated Primary Completion Date :||December 1, 2018|
|Estimated Study Completion Date :||December 30, 2018|
Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
Procedure: Photodynamic Therapy
PDT is a therapeutic approach that specifically targets neoplastic cells.
• PDT involves three components:
Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.
Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months.
Other Name: PDT
- Safety [ Time Frame: 3 years ]Documentation of Safety: Number of Participants with Adverse Events; Type, frequency and intensity of adverse events
- Efficacy [ Time Frame: 3 years ]
Documentation of efficacy: Technical and clinical success rates; and survival duration.
Effectiveness will be assessed by visual inspection of tissue necrosis in the bile ducts one month post photo dynamic therapy delivery.
- Concomitant Therapy Effect [ Time Frame: 3 years ]Documentation of concomitant/adjuvant therapy and overall survival duration.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01524146
|Contact: Michel Kahaleh, M.D.||email@example.com|
|Contact: Monica Gaidhane, MPHfirstname.lastname@example.org|
|United States, New York|
|Weill Cornell Medical College||Recruiting|
|New York, New York, United States, 10021|
|Contact: Michel Kahaleh, MD 646-962-4000 email@example.com|
|Contact: Monica R Gaidhane, MD, MPH 646-962-4796 firstname.lastname@example.org|
|Principal Investigator: Michel Kahaleg, MD|
|Weill Medical College of Cornell University||Active, not recruiting|
|New York, New York, United States, 10021|
|Principal Investigator:||Michel Kahaleh, M.D.||Weill Medical College of Cornell University|